MINI-BEAM AS SALVAGE CHEMOTHERAPY FOR REFRACTORY HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA

被引：22

作者：

STEWART, AK ^{[1
]}

BRANDWEIN, JM ^{[1
]}

SUTCLIFFE, SB ^{[1
]}

SCOTT, JG ^{[1
]}

KEATING, A ^{[1
]}

机构：

[1] UNIV TORONTO,TORONTO HOSP,AUTOLOGOUS BONE MARROW TRANSPLANT PROGRAM,TORONTO GEN DIV,TORONTO M5G 2C4,ONTARIO,CANADA

来源：

LEUKEMIA & LYMPHOMA | 1991年 / 5卷 / 2-3期

关键词：

MINIBEAM; SALVAGE CHEMOTHERAPY; REFRACTORY HODGKINS DISEASE; REFRACTORY NON-HODGKINS LYMPHOMA;

D O I：

10.3109/10428199109068113

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Long-term disease-free survival after conventional dose salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) is rare. Intensive chemotherapy and autologous bone marrow transplantation (ABMT) is regarded by many as the treatment of choice. For lymphoma, eligibility for transplant is frequently restricted to cases with chemotherapy-sensitive disease or minimal tumour bulk. We evaluated the mini-BEAM regimen as further treatment for patients unresponsive to initial salvage therapy and thus ineligible for ABMT at our centre. Carmustine 60 mg/m2 I.V. day one, etoposide 75 mg/m2 I.V. days 2-5, cytosine arabinoside 100 mg/m2 I.V. q12h days 2-5 and melphalan 30 mg/m2 day 6 (mini-BEAM) was administered to 24 patients with lymphoma, 22 of whom were refractory to at least first-line salvage chemotherapy. Eleven had HD and 13 NHL. The complete response (CR) rate was 21% and the overall response was 59%. Febrile neutropenia occurred in 48% of treatment episodes. There were two treatment-related deaths. Thirteen patients underwent bone marrow transplantation (BMT), 11 received ABMT (8 HD, 3 NHL). Six patients did not achieve remission after transplant but 7 patients remain in continuous CR, with a follow-up of 6-17 months post-transplant. Consequently, 7 of 24 (29%) patients responded to mini-BEAM and many achieve long-term disease-free survival after BMT. Further evaluation of mini-BEAM as a salvage regimen prior to BMT is indicated. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：111 / 115

页数：5

共 13 条

[1]

Santoro A., Bonfante V., Bonadonna G., Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease, Ann Intern Med, 96, pp. 139-143, (1982)

[2]

Harker W.G., Kuslan P., Rosenberg S.A., Combination chemotherapy for advanced Hodgkin’s disease after failure of MOPP:ABVD and B-CAVe, Ann Intern Med, 101, pp. 440-446, (1984)

[3]

Bonadonna G., Viviani S., Valagussa P., Bonfante V., Santoro A., Third-line salvage chemotherapy in Hodgkin’s disease, Semin Oncol, 7, 2, pp. 1-25, (1985)

[4]

Buzaid A.C., Lippman S.M., Miller T.P., Salvage therapy of advanced Hodgkin’s disease, Am J Med, 83, pp. 523-532, (1987)

[5]

Velasquez W.S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., Tucker S., Jagannath S., Hagemeister F.B., Redman J.R., Swan F., Barlogie B., Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and Dexamethasone (DHAP), Blood, 71, pp. 1-122, (1988)

[6]

Brandwein J.M., Callum J., Sutcliffe S.B., Scott J.G., Keating A., Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin’s disease, Bone Marrow Transplantation, 5, pp. 99-103, (1990)

[7]

Cabanillas F., Hagemeister F.B., McLauglin P., Velasquez W.S., Riggs S., Fuller L., Smith T., Results of MIME salvage regimen for recurrent or refractory lymphoma, J Clin Oncol, 5, 3, pp. 407-412, (1987)

[8]

Philip T., Armitage J.O., Spitzer G., Spitzer G., Chauvin F., Jagannath S., Cahn J.Y., Colombat P., Goldstone A.H., Gorin N.C., Flesh M., High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high-grade non-Hodgkin’s lymphoma, N Engl J Med, 316, 24, pp. 1493-1498, (1987)

[9]

Gribben J.G., Goldstone A.H., Linch D.C., Taghipour G., McMillan A.K., Souhami R.L., Earl H., Richards J.D., Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin’s lymphoma who are still responsive to conventional-dose therapy, J Clin Oncol, 7, 11, pp. 1621-1629, (1989)

[10]

Gribben J.G., Linch D.C., Singer C.R., McMillan A.K., Jarrett M., Goldstone A.H., Successful treatment of refractory Hodgkin’s disease by high dose combination chemotherapy and autologous bone marrow transplantation, Blood, 73, 1, pp. 340-344, (1989)

← 1 2 →